Advertisement

Glucocorticoid sparing in sarcoidosis using the Janus kinase (JAK) inhibitor tofacitinib

Published:December 23, 2021DOI:https://doi.org/10.1016/j.ejim.2021.12.016
      There is an unmet medical need to provide novel treatments with high efficiency and low side effects in patients with sarcoidosis resistant to glucocorticoids or second-line therapies (methotrexate, TNFα inhibitors), or who cannot tolerate them [
      • Drent M.
      • Crouser E.D.
      • Grunewald J.
      Challenges of sarcoidosis and its management.
      ].

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Drent M.
        • Crouser E.D.
        • Grunewald J.
        Challenges of sarcoidosis and its management.
        N Engl J Med. 2021; 385: 1018-1032https://doi.org/10.1056/nejmra2101555
        • Ramstein J.
        • Broos C.E.
        • Simpson L.J.
        • Mark Ansel K.
        • Sun S.A.
        • Ho M.E.
        • et al.
        IFN-γproducing t-helper 17.1 cells are increased in sarcoidosis and are more prevalent than t-helper type 1 cells.
        Am J Respir Crit Care Med. 2016; 193: 1281-1291https://doi.org/10.1164/rccm.201507-1499OC
        • Damsky W.
        • Thakral D.
        • Emeagwali N.
        • Galan A.
        • King B.
        Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis.
        N Engl J Med. 2018; 379: 2540-2546https://doi.org/10.1056/nejmoa1805958
        • Talty R.
        • Damsky W.
        • King B.
        Treatment of cutaneous sarcoidosis with tofacitinib: a case report and review of evidence for Janus kinase inhibition in sarcoidosis.
        JAAD Case Rep. 2021; 16: 62-64https://doi.org/10.1016/j.jdcr.2021.08.012
        • Kerkemeyer K.L.
        • Meah N.
        • Sinclair R.D.
        Tofacitinib for cutaneous and pulmonary sarcoidosis: a case series.
        J Am Acad Dermatol. 2021; 84: 581-583https://doi.org/10.1016/j.jaad.2020.10.016
        • Friedman M.A.
        • Le B.
        • Stevens J.
        • Desmarais J.
        • Seifer D.
        • Ogle K.
        • et al.
        Tofacitinib as a Steroid-Sparing Therapy in Pulmonary Sarcoidosis, an Open-Label Prospective Proof-of-Concept Study.
        Lung. 2021; 199: 147-153https://doi.org/10.1007/s00408-021-00436-8
        • Zhou T.
        • Casanova N.
        • Pouladi N.
        • Wang T.
        • Lussier Y.
        • Knox K.S.
        • et al.
        Identification of Jak-STAT signaling involvement in sarcoidosis severity via a novel microRNA-regulated peripheral blood mononuclear cell gene signature.
        Sci Rep. 2017; 7https://doi.org/10.1038/s41598-017-04109-6
        • Damsky W.
        • Thakral D.
        • McGeary M.K.
        • Leventhal J.
        • Galan A.
        • King B.
        Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare.
        J Am Acad Dermatol. 2020; 82: 612-621https://doi.org/10.1016/j.jaad.2019.05.098